Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV003481671 | SCV004225954 | uncertain significance | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | PP2 |
Labcorp Genetics |
RCV005100290 | SCV005834497 | uncertain significance | Ehlers-Danlos syndrome, type 4 | 2024-03-07 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 941 of the COL3A1 protein (p.Pro941Leu). This variant is present in population databases (rs747784033, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with COL3A1-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |